Healthcare costs associated with initial maintenance therapy with fluticasone propionate 250 μg/salmeterol 50 μg combination versus anticholinergic bronchodilators in elderly US Medicare-eligible beneficiaries with COPD

Abstract

Objective: To compare, in elderly Medicare beneficiaries, chronic obstructive pulmonary disease (COPD)-related healthcare costs for patients initiating treatment with fluticasone propionate/salmeterol 250 μg/50 μg (FSC) with those for patients initiating treatment with ipratropium bromide/albuterol (IPA), ipratropium bromide (IPR), and tiotropium bromide (TIO).

Methods: In this retrospective, observational, cohort study, COPD-related medical costs (inpatient/emergency department, outpatient) and pharmacy costs were assessed in Medicare beneficiaries ≥65 years old who were enrolled in a commercial Medicare health maintenance organization plan and had a diagnosis of COPD (ICD-9-CM codes 491.xx, 492.xx, or 496.xx) within 12 months before initial treatment with FSC, IPA, IPR, or TIO.

Results: In these ≥65-year-old patients (N=14,689), initial maintenance treatment with FSC was associated with total COPD-related cost savings (medical + pharmacy) of $295 versus IPA, $1,235 versus IPR, and $110 versus TIO (p<0.05, each comparison) over a 1-year follow-up period.

Conclusions: Initiation of maintenance therapy with FSC was associated with significant reduction in total costs (medical + pharmacy) relative to costs associated with the short-acting anticholinergic bronchodilators IPR and IPA and the long-acting anticholinergic bronchodilator TIO in an elderly Medicare-eligible population. These data considered in the context of the substantial efficacy and effectiveness data suggest that early introduction of maintenance treatment with FSC has both clinical and economic benefits. Limitations inherent in handling of administrative data include lack of objective clinical measures such as spirometry and smoking status. Furthermore, accuracy of diagnosis codes cannot be verified.

Key words::

• bronchodilator
• chronic obstructive pulmonary disease (COPD)
• corticosteroid
• cost
• fluticasone/salmeterol
• pharmacoeconomics

Acknowledgments

Declaration of interest: GlaxoSmithKline funded the study described in this manuscript. A.A.D. has disclosed that he is employed by GlaxoSmithKline. H.P. and C.M.B. have disclosed that they have received research funding from GlaxoSmithKline and other pharmaceutical companies on similar topics, and C.M.B. serves as a consultant to GlaxoSmithKline, and other pharmaceutical companies in respiratory disease research. L.S-W has disclosed that she has received research funding from GlaxoSmithKline for similar research. The authors acknowledge Jane Saiers, PhD, for assistance with writing the manuscript. GlaxoSmithKline funded Dr. Saiers’ work.